跳至主要内容
临床试验/ITMCTR2100004816
ITMCTR2100004816招募中1 期

Efficacy and Safety of Zhitan Anshen Granules in Motor Dysfunction After Cerebral Infarction: a Randomized, Double-Blind, Placebo-Controlled Clinical Trial

Hubei Provincial Hospital of Integrated Chinese and Western Medicine0 个研究点开始时间: 待定最近更新:
适应症

试验速览

阶段
1 期
状态
招募中
发起方

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional study

入排标准

年龄范围
40 至 75(—)
性别
All

入选标准

  • 1. Meet the diagnostic criteria for cerebral infarction, and be confirmed by head CT or MRI;
  • 2. Meet the standard of Chinese medicine stroke-qi deficiency and blood stasis syndrome type;
  • 3. In the recovery period (the course of illness is between 2 weeks and 6 months)
  • 4. Aged 40 to 75 years;
  • 5. First stroke, stable vital signs, clear consciousness, able to cooperate with examination and treatment;
  • 6. Having motor dysfunction and Fugl-Meyer score <= 84 points;
  • 7. Sign the informed consent form.

排除标准

  • 1. Patients with severe cardiovascular, cerebrovascular, liver, kidney, malignant tumors, hematological diseases, and mental diseases;
  • 2. Severe disturbance of consciousness, dementia or suffering from certain diseases affect the evaluation of curative effects, such as aphasia, visual and hearing impairment;
  • 3. Transient organic psychosis and other mental illnesses (such as depression, schizophrenia), or other mental disorders that meet the DSM-IV-R standards;
  • 4. Patients who have other diseases that affect the function of limbs, and those who have dysfunction of limbs caused by claudication, osteoarthritis, rheumatoid arthritis, gouty arthritis, etc. before treatment may affect nerve or functional examination;
  • 5. Patients who are allergic to test drug components, or have a history of alcohol or drug abuse;
  • 6. Women who are pregnant or breastfeeding, or have a pregnancy plan in the past 6 months, or cannot use effective contraceptive measures (sterilization, long-term use of contraceptives/drugs, condoms, or removal of the vas deferens from their partners, etc.);
  • 7. Participating in other clinical trials or participating in other drug clinical trials within 3 months.
  • 8. Patients judged by the investigator to be unsuitable to participate in this trial.

研究者

发起方
Hubei Provincial Hospital of Integrated Chinese and Western Medicine

相似试验

Efficacy and Safety of Zhitan Anshen Granules in... | 临床试验